Can a new drug stop inherited Alzheimer's in its tracks?
NCT ID NCT06384573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests lecanemab, an antibody that targets amyloid plaques in the brain, in 40 people who carry a gene mutation that causes early-onset Alzheimer's. Participants previously received another anti-amyloid drug and will now receive lecanemab to see if it can fully clear amyloid plaques and slow cognitive decline. The goal is to understand whether aggressive amyloid removal can delay or prevent the onset of dementia in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lecanemab (also called BAN2401), given as an intravenous infusion
What this could lead to
If successful, this could show that removing amyloid plaques delays or slows the progression of inherited Alzheimer's disease, offering a potential treatment for this rare form.
What could go wrong
This is a small, open-label study with no placebo group, so results may be less reliable. The drug may not fully remove plaques or meaningfully slow the disease, and side effects like brain swelling or bleeding are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia
-
The National Hospital for Neurology and Neurosurgery
London, Greater London, WC1B 3BG, United Kingdom
-
University of Alabama in Birmingham
Birmingham, Alabama, 35294, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States